fda approved semaglutide compound The Risks of Compounded Products Not all “GLP-1 pills” are

Many users start experiencing reduced appetite, increased fullness, or fewer cravings within the first one to two weeks, while weight loss often takes several weeks to become noticeable

Refrigerate for optimal quality

The FDA approved semaglutide under the brand name Wegovy specifically for chronic weight management in 2021

However, compounded drug products such as semaglutide, pose a higher risk to patients than FDA-approved drug products because compounded drug products do not undergo FDA safety checks

Wegovy and Zepbound are the most reported medications: 45% of all shortage reports are for Wegovy 34% of all shortage reports are for Zepbound 19% of all shortage reports are for Ozempic and Mounjaro, GLP-1s indicated for type-2 diabetes Starter doses are the most often reported: Wegovy 0.25mg is the most commonly reported dosage, appearing in about twice as many reports as other Wegovy doses